checkAd
    Startseite > Aktien > Precision BioSciences > Nachrichten
    Precision BioSciences
    Aktie
    ISIN: US74019P2074 WKN: A400AS SYM: PBS0 Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    11,200
     
    EUR
    -0,100 EUR
    -0,88 %
    Letzter Kurs 11.06.24 Tradegate
    Geldkurs
    08:00:14
    11,100
     
    EUR
    273 STK
    Briefkurs
    08:00:14
    11,300
     
    EUR
    265 STK

    Precision BioSciences Aktie kaufen

    Kauf
    Verkauf
    ISIN: US74019P2074 WKN: A400AS SYM: PBS0 Land USA

    Neueste Nachrichten

    Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
    05.06.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences to Participate in Upcoming June Investor Conferences
    30.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    17.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    13.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
    08.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences to Report First Quarter Results on May 13, 2024
    07.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
    07.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
    01.05.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
    16.04.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
    27.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
    20.03.24 · Business Wire (engl.) · Precision BioSciences
    Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
    19.03.24 · Business Wire (engl.) · Precision BioSciences